Inthe U.S., peanut allergy is present in 0.6% of the population. Amongchildren in the Western world, rates are between 1.5% and 3% and haveincreased over time. This has led to increasing investment in PeanutAllergy Vaccine.In December 2020, researchers at University of South Australia andSementis received an NHMRC Ideas Grant that will support the team tobetter understand the immune signatures critical to modulating immuneresponses to allergens.
Itseems that when looking for treatments, there are two that constantlycome up: PeanutAllergy Vaccineand Vaximab. Both of these are FDA approved but there are many peoplewho question the efficiency of using human samples in treatingdiseases. Human samples cannot work at full capacity due to thevarious levels of gluten they may contain. It is also important tonote that Vaximab clinical trial has not yet begun.
ReadMore@ https://bit.ly/3d2LT9G